Coronavirus: Vaccination
(asked on 15th December 2025) - View Source
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of the Autumn 2025 Covid-19 vaccination eligibility criteria on people with asthma; what consideration was given to including asthma as a qualifying condition for free Covid vaccination; and what assessment he has made of the affordability and pricing of privately purchased Covid vaccines for those no longer eligible for free vaccination.
The Government is committed to protecting those most vulnerable to COVID-19 through vaccination, as guided by the independent Joint Committee on Vaccination and Immunisation (JCVI). The primary aim of the national COVID-19 vaccination programme remains the prevention of serious illness, resulting in hospitalisations and deaths, arising from COVID-19.
The JCVI has advised that population immunity to COVID-19 has increased due to a combination of naturally acquired immunity following recovery from infection and vaccine-derived immunity. COVID-19 is now a relatively mild disease for most people, though it can still be unpleasant, with rates of hospitalisation and death from COVID-19 having reduced significantly since COVID-19 first emerged.
The focus of the JCVI advised programme has therefore moved towards targeted vaccination of the two groups who continue to be at higher risk of serious disease, including mortality. These are the oldest adults and individuals who are immunosuppressed.
The Government has accepted the JCVI advice for autumn 2025 and in line with the advice, a COVID-19 vaccination is being offered to the following groups:
- adults aged 75 years old and over;
- residents in care homes for older adults; and
- individuals aged six months old and over who are immunosuppressed.
As with other United Kingdom vaccination programmes, the JCVI’s advice on eligibility for COVID-19 vaccination carefully considers the evidence on the risk of illness, serious disease, or death as a consequence of infection, in specific groups, as well as cost-effectiveness analysis. Further detail can be found at the following link:
The JCVI keeps all vaccination programmes under review.
As with other vaccines provided privately, the availability and price of COVID-19 vaccines provided through the private market is a matter for the companies concerned. All those eligible to receive a COVID-19 vaccination this autumn through the National Health Service, in line with advice by the independent expert JCVI, are encouraged to take up this offer. The national programme launched on 1 October 2025 and runs until 31 January 2026.